<DOC>
	<DOCNO>NCT01153763</DOCNO>
	<brief_summary>BRF113710 Phase II , single-arm , open-label study ass efficacy , safety , tolerability GSK2118436 administer twice daily single agent subject BRAF mutant metastatic melanoma . Subjects receive 150 mg GSK2118436 twice daily continue treatment disease progression , death , unacceptable adverse event .</brief_summary>
	<brief_title>A Study GSK2118436 BRAF Mutant Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Must least 18 year age Must histologically confirm cutaneous metastatic melanoma ( Stage IV ) BRAF mutationpositive ( V600 E/K ) determine via central test BRAF mutation assay . Is treatment naive receive prior treatment metastatic melanoma . Must measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) . Women childbearing potential must negative pregnancy test within 14 day prior first dose study treatment . Women reproductive potential must willing practice acceptable method birth control study 4 week last dose study medication . Men reproductive potential must willing practice acceptable method birth control study 16 week last dose study medication . Must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 . Adequate organ function . Previous treatment BRAF MEK inhibitor . Cancer therapy ( chemotherapy delay toxicity , radiation therapy , immunotherapy , biologic therapy , major surgery ) within last 3 week ; chemotherapy regimens without delayed toxicity within last 2 week ; use investigational anticancer drug within 28 day 5 halflives , whichever longer , precede first dose GSK2118436 . A history know Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection . History evidence brain metastasis MRI head CT MRI able perform . History malignancy . Subjects diseasefree 5 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . Certain cardiac abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic melanoma</keyword>
	<keyword>BRAF mutant</keyword>
	<keyword>Melanoma</keyword>
	<keyword>BRAF mutant metastatic melanoma</keyword>
</DOC>